Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eye (Lond) ; 38(6): 1097-1103, 2024 Apr.
Article in English | MEDLINE | ID: mdl-37968517

ABSTRACT

OBJECTIVE: Evaluation of optical coherence tomography biomarkers in predicting treatment response to intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) Bevacizumab, in aggressive retinopathy of prematurity (A-ROP). METHODS: Non-contact ultra-widefield (NC-UWF) fundus imaging with integrated UWF guided swept source Optical coherence tomography (SS-OCT) was performed prospectively in preterm babies before and after intravitreal anti-VEGF (Bevacizumab) monotherapy. OCT biomarkers were analysed in eyes that reached complete vascularization versus others. RESULTS: Eyes with retinal vessels reaching near ora serrata were labelled as regressed ROP and vascularised retina (Group1). Eyes with reactivation of ROP needing laser or vitreoretinal surgery or eyes with peripheral avascular retina (PAR) at 16th week post-injection were considered as Group 2. Pre-injection baseline OCT showed a hyperreflectivity of inner retinal layers in 12 out of 46 eyes in Group 1 versus 30 out of 34 eyes in Group 2 (p value 0.002). None of the eyes in Group 1 showed choroidal thinning at posterior pole as compared to 14 out of 34 eyes in Group 2 (p value 0.001). Intraretinal hypo reflective Cystic changes at fovea were seen in 16 out of 46 eyes in Group 1 and 2 out of 34 eyes in Group 2 (p value 0.012). CONCLUSION: Pre-injection swept source OCT biomarkers could predict the treatment outcomes of anti-VEGF (Bevacizumab) monotherapy in A-ROP eyes. Hyperreflectivity of inner retinal layers and choroidal thinning had poorer and unpredictable response to anti-VEGF injection whereas, cystic changes at fovea predicted favourable response.


Subject(s)
Angiogenesis Inhibitors , Retinopathy of Prematurity , Infant, Newborn , Infant , Humans , Bevacizumab/therapeutic use , Angiogenesis Inhibitors/therapeutic use , Tomography, Optical Coherence , Endothelial Growth Factors/therapeutic use , Retinopathy of Prematurity/diagnosis , Retinopathy of Prematurity/drug therapy , Vascular Endothelial Growth Factor A/therapeutic use , Intravitreal Injections , Biomarkers , Retrospective Studies , Gestational Age
2.
Eye (Lond) ; 37(9): 1904-1909, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36195674

ABSTRACT

OBJECTIVE: To illustrate the role of non-contact widefield retinal imaging (NC-WFI) of retinopathy of prematurity (ROP) using the Clarus 700 high resolution true colour reflectance imaging. METHODS: All babies were examined by the vitreoretinal faculty in a tertiary eye care centre from a period of March 2021 to November 2021 using the indirect ophthalmoscope after pupillary dilatation. ROP grading was done according to the revised ICROP (2005) classification. NC-WFI was then performed using the Clarus 700 high resolution true colour reflectance imaging (Carl Zeiss Meditec, Dublin, CA) in the retina diagnostic set up of a tertiary eye care centre. RESULTS: A total of 22 babies (44 eyes) underwent NC-WFI from March 2021 to November 2021. 13 unique cases of retinopathy of prematurity with images captured on Clarus 700 and the clinical summary is described. CONCLUSION: Clarus is a non-contact wide field imaging (NC-WFI) system that can capture high resolution and true colour images (images of the fundus appear similar colour to direct observation by ophthalmoscopy) helping in more accurate diagnosis and grading of the severity of ROP.


Subject(s)
Retinopathy of Prematurity , Infant, Newborn , Infant , Humans , Retinopathy of Prematurity/diagnosis , Color , Retina/diagnostic imaging , Ophthalmoscopy/methods , Fundus Oculi
SELECTION OF CITATIONS
SEARCH DETAIL
...